Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 5/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209307 | 0.96 | SIGMAR1 (0.71) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| SCHEMBL3457736 | 0.92 | SIGMAR1 (0.69) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| SCHEMBL11465528 | 0.91 | SIGMAR1 (0.76) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11280918 | 0.90 | SIGMAR1 (0.67) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| SCHEMBL2090542 | 0.86 | SIGMAR1 (0.69) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| SCHEMBL11405931 | 0.86 | SIGMAR1 (0.69) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| SCHEMBL1253143 | 0.86 | SIGMAR1 (0.69) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| SCHEMBL9559659 | 0.86 | SIGMAR1 (0.69) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| SCHEMBL13875120 | 0.86 | SIGMAR1 (0.69) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 | |
| SCHEMBL13875122 | 0.85 | SIGMAR1 (0.71) | SIGMAR1CYP2D6HTR1AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4556007-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-120000655-A | Use of N- {4- [ (4-methylbenzyl) oxy ] benzyl } -N- (4-piperidylmethyl) amine | 南京大学 | 2025-05-16 | — | — | CN | disclosed |
| WO-2024012554-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | 上海日馨医药科技股份有限公司 | 2024-01-18 | — | — | WO | disclosed |
| EP-0771197-B1 | USE OF HETEROCYCLIC COMPOUNDS AS DOPAMINES-D 3- LIGANDS | BASF AG (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-6090807-A | Use of heterocyclic compounds | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-18 | — | — | US | disclosed |
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | disclosed |
| US-5591743-A | ANXIOLYTIC DRUGS OR HYPOTENSIVE AGENTS | PIERRE FABRE MEDICAMENT (FR) | 1997-01-07 | — | — | US | disclosed |
| EP-0707571-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001965-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1995-01-19 | — | — | WO | disclosed |
| US-4585773-A | DIURETIC, HYPOTENSIVE | BRISTOL-MYERS COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0048045-A1 | Phenyl piperazine derivatives having antiagressive activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | SIGMAR1 1229/4885CYP2D6 232/4885HTR1A 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.